Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Peptic Ulcer Disease I: Introduction01:30

Peptic Ulcer Disease I: Introduction

689
Peptic Ulcer Disease (PUD) is characterized by mucosal excavation in the esophagus, stomach, pylorus, or duodenum. It can manifest as acute or chronic based on the extent and duration of mucosal involvement.
An acute ulcer, marked by superficial erosion and minimal inflammation, swiftly resolves upon identifying and addressing the underlying cause. In contrast, a chronic ulcer persists, potentially eroding through the muscular wall and forming fibrous tissue.
Peptic ulcers can also be...
689
Peptic Ulcer Disease II: Pathophysiology01:28

Peptic Ulcer Disease II: Pathophysiology

1.8K
Peptic Ulcer Disease (PUD) is characterized by the development of ulcers in the stomach or duodenal mucosa. Its pathophysiology is complex, involving a balance between damaging and protective elements.
Damaging agents such as Helicobacter pylori, gastric acid, pepsin, and nonsteroidal anti-inflammatory drugs (NSAIDs) can weaken the mucosal defense, allowing hydrogen ions to infiltrate back and harm epithelial cells.
1.8K
Peptic Ulcer Disease IV: Management01:26

Peptic Ulcer Disease IV: Management

374
Medical treatment strategies for peptic ulcers encompass various methods. The primary goal of treatment is to diminish gastric acidity and strengthen mucosal defense mechanisms.
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...
374
Peptic Ulcer Disease V: Surgical Management and Nursing Care01:25

Peptic Ulcer Disease V: Surgical Management and Nursing Care

746
Surgical management and nursing care are crucial in treating Peptic Ulcer Disease (PUD). Here is an organized and enhanced overview of the surgical interventions and the associated nursing care for PUD:
Surgical Interventions for Peptic Ulcer Disease
746
Acid Suppressive Drugs for Peptic Ulcer Disease: Proton Pump Inhibitors01:13

Acid Suppressive Drugs for Peptic Ulcer Disease: Proton Pump Inhibitors

774
Peptic ulcers, often induced by H. pylori infections or NSAID usage, arise from disruptions in the delicate balance of gastric acid production. Peptic ulcers stem from heightened gastric acid levels due to H. pylori infections or NSAID use. The protective mucus layer diminishes in the presence of these factors, allowing gastric acid to erode the stomach lining and form ulcers.
Gastric acid, a potent cocktail of hydrogen and chloride ions, is produced in specialized parietal cells within the...
774
Peptic Ulcer Disease III: Clinical Manifestations and Diagnostic Studies01:28

Peptic Ulcer Disease III: Clinical Manifestations and Diagnostic Studies

479
Peptic ulcer disease (PUD) presents with diverse symptoms depending on the location and severity of the ulcer. Clinical manifestations of peptic ulcer include dull pain and a burning sensation in the mid-epigastric region.
Few clinical manifestations differentiate gastric ulcers from duodenal ulcers. Distinctions in the location, timing, and pain relief are crucial for healthcare providers in differentiating between gastric and duodenal ulcers during clinical assessments.
479

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Review Article: Implementation Challenges in Helicobacter pylori Management: Bridging Evidence and Real-World Practice.

Alimentary pharmacology & therapeutics·2026
Same author

Deletion of endothelial SOX9 reverses aging-induced cardiac dysfunction.

Cardiovascular research·2026
Same author

Elucidating the Pathogenic Role of Helicobacter pylori Infection in Hematologic Disorders: Mechanistic Insights and Future Perspectives.

Helicobacter·2026
Same author

CCR2<sup>+</sup> Neutrophils Exhibit a Proinflammatory Phenotype and Contribute to Plaque Vulnerability.

Arteriosclerosis, thrombosis, and vascular biology·2026
Same author

Author Correction: The AIM2 inflammasome exacerbates atherosclerosis in clonal haematopoiesis.

Nature·2026
Same author

Deletion of PKM2 in Macrophages Promotes Stabilization but Not Regression of Atherosclerotic Plaques.

Circulation research·2026
Same journal

Pancreatitis in Familial Dysautonomia Patients.

Digestive diseases (Basel, Switzerland)·2026
Same journal

Treatment outcomes with empirical Clarithromycin-based triple therapy for Helicobacter pylori in Zambia, sub-Saharan Africa.

Digestive diseases (Basel, Switzerland)·2026
Same journal

Endoscopic submucosal dissection-associated bacteremia: proper antibiotic management.

Digestive diseases (Basel, Switzerland)·2026
Same journal

The investigation and treatment of Helicobacter pylori for the prevention of gastric cancer: A narrative review and assessment of management approaches.

Digestive diseases (Basel, Switzerland)·2026
Same journal

Analysis of Helicobacter pylori resistance and its trends in Chongqing: A 10-year retrospective study.

Digestive diseases (Basel, Switzerland)·2026
Same journal

Early-onset colorectal cancer in Australia: environmental, microbial, and policy implications.

Digestive diseases (Basel, Switzerland)·2026
See all related articles

Related Experiment Video

Updated: Dec 31, 2025

Author Spotlight: Advancing Early Detection and Treatment of Gastrointestinal Tumors
03:05

Author Spotlight: Advancing Early Detection and Treatment of Gastrointestinal Tumors

Published on: February 16, 2024

1.4K

Peptic Ulcer: Chapter Closed?

Peter Malfertheiner1,2, Christian Schulz3

  • 1Department of Medicine II, University Hospital, LMU Munich, Munich, Germany, peter.malfertheiner@med.uni-muenchen.de.

Digestive Diseases (Basel, Switzerland)
|January 7, 2020
PubMed
Summary
This summary is machine-generated.

Peptic ulcer disease (PUD) has decreased, but complications persist in the elderly. While Helicobacter pylori eradication offers a cure, antibiotic resistance presents new challenges for treating this evolving condition.

Keywords:
Acid suppressantsEpidemiological trendsHelicobacter pylori eradicationPeptic ulcer diseaseUlcer complications

More Related Videos

Author Spotlight: Point-of-Care Ultrasound for Gastric Content Assessment and Risk Stratification in Perioperative Care
05:50

Author Spotlight: Point-of-Care Ultrasound for Gastric Content Assessment and Risk Stratification in Perioperative Care

Published on: September 22, 2023

4.1K
The Dyspepsia Educational Tool As a Novel Aid in Dyspepsia Management
06:40

The Dyspepsia Educational Tool As a Novel Aid in Dyspepsia Management

Published on: June 29, 2019

6.9K

Related Experiment Videos

Last Updated: Dec 31, 2025

Author Spotlight: Advancing Early Detection and Treatment of Gastrointestinal Tumors
03:05

Author Spotlight: Advancing Early Detection and Treatment of Gastrointestinal Tumors

Published on: February 16, 2024

1.4K
Author Spotlight: Point-of-Care Ultrasound for Gastric Content Assessment and Risk Stratification in Perioperative Care
05:50

Author Spotlight: Point-of-Care Ultrasound for Gastric Content Assessment and Risk Stratification in Perioperative Care

Published on: September 22, 2023

4.1K
The Dyspepsia Educational Tool As a Novel Aid in Dyspepsia Management
06:40

The Dyspepsia Educational Tool As a Novel Aid in Dyspepsia Management

Published on: June 29, 2019

6.9K

Area of Science:

  • Gastroenterology
  • Internal Medicine
  • Epidemiology

Background:

  • Peptic ulcer disease (PUD) incidence peaked in the late 19th/early 20th century, declining significantly in the 21st century.
  • Demographic shifts, including an aging population with comorbidities and polypharmacy, contribute to persistent PUD complications.
  • The historical acid-suppression model for PUD management has been largely superseded by the understanding of Helicobacter pylori's role.

Purpose of the Study:

  • To review the evolving landscape of peptic ulcer disease.
  • To highlight the impact of Helicobacter pylori and emerging antibiotic resistance.
  • To discuss current challenges in PUD etiology identification and management.

Main Methods:

  • Literature review of PUD incidence, etiologies, and treatment modalities.
  • Analysis of demographic trends influencing PUD complications.
  • Discussion of therapeutic advancements and challenges, including H. pylori eradication and antibiotic resistance.

Main Results:

  • Proton pump inhibitors rapidly resolve symptoms but do not cure PUD.
  • Helicobacter pylori eradication has transformed PUD into a curable disease.
  • Increasing antibiotic resistance in H. pylori leads to treatment failures.
  • Non-H. pylori etiologies are becoming more prevalent, necessitating accurate diagnosis.

Conclusions:

  • Peptic ulcer disease management requires identifying the specific ulcerogenic cause for tailored therapy.
  • Effective management of peptic ulcer bleeding remains a significant clinical challenge.
  • While PUD has become more heterogeneous, its study and treatment are ongoing.